KYE Pharmaceuticals Inc. today announced it has submitted a New Drug Submission (NDS) to Health Canada for the regulatory review and approval of Accrufer® (ferric maltol). If approved, Accrufer® would be the first prescription only oral iron therapy approved by Health Canada and marketing approval for Accrufer® is expected to be during the first half…
eTurboNews atik yo se pou abonnés sèlman. Abònman se GRATIS.
Abonnés konekte isit la Klike la a pou w abònman GRATIS
Abonnés konekte isit la Klike la a pou w abònman GRATIS
KISA POU RETIRE NAN ATIK SA A:
- jodi a te anonse li te soumèt yon Nouvo Soumèt Medikaman (NDS) bay Health Canada pou revizyon regilasyon ak apwobasyon Accrufer® (ferric maltol).
- If approved, Accrufer® would be the first prescription only oral iron therapy approved by Health Canada and marketing approval for Accrufer® is expected to be during the first half….
- eTurboNews atik yo se pou abonnés sèlman.
